GuShiio.com ① Hanbang Technology and Yingshi Innovation IPOs are both registered and effective. The investors behind Hanbang Technology include Huajin Capital, Junlian Capital, Sequoia China, Zheshang Venture Capital, WuXi AppTec, Zero 2 Venture Capital, etc.;
② Among them, Hanbang Technology hit the IPO process quite rapidly.
“Science and Technology Innovation Board Daily”, March 9 (Reporter Yu Jiaxin) This week (March 3 to March 9), the two companies planning to IPOs on the Science and Technology Innovation Board have updated their progress, and the IPOs of Hanbang Technology and Yingshi Innovation are both in the registration and effective stage.
Among them,Hanbang Technology has hit the IPO process quite quickly: the China Securities Regulatory Commission issued a reply on March 4 this year approving the registration of Hanbang Technology’s initial public offering; the company’s IPO officially registered and took effect on March 6, which is less than two weeks after its submission for registration.
Hanbang Technology is a company with chromatography technology as its core and integrating research and development, production and sales. It mainly provides professional separation and purification equipment, consumables, application technical services and related technical solutions in the fields of pharmaceuticals, life sciences and other fields.
The prospectus shows that at the end of each period from 2021 to 2024, Hanbang Technology achieved revenue of 320 million yuan, 480 million yuan, 619 million yuan, and 690 million yuan respectively; net profit was 4.86 million yuan, 38.56 million yuan, 51.5 million yuan, and 79.34 million yuan respectively.
Hanbang Technology expects revenue in the first quarter of 2025 to be 145 million to 162 million yuan, a year-on-year increase of 5.13% to 17.53%; net profit will be 8.4 million yuan to 14.1 million yuan, a year-on-year increase of 46.60% to 146.08%.
In terms of investment funds, at the end of 2023, when Hanbang Technology submitted its application materials for the first time, it planned to raise 980 million yuan to expand production, research and development and replenish working capital. In its latest application draft, the amount raised has been significantly reduced to 598 million yuan. Among them, supplementary working capital projects were cancelled, and R & D projects were changed to partially rely on self-raised funds. Only the production capacity expansion projects remained unchanged.
According to the plan, Hanbang Technology plans to use fundraising to expand production capacity. After the project is completed, it will add 1000 units of liquid chromatography series separation equipment production capacity and 2000 units (sets) of laboratory chromatography separation and purification instruments, with a construction period of 2 years.
Sky Eye Inspection shows that Hanbang Technology has gone through 8 rounds of financing, with investors including Huajin Capital, Junlian Capital, Sequoia China, Zheshang Venture Capital, WuXi AppTec, Zero 2 IPO Venture Capital, etc.
According to its prospectus, before this issuance, Zhang Dabing directly held 31.67% of Hanbang Technology’s shares and was the controlling shareholder. It also controls 2.94%, 2.67% and 1.30% of the company’s shares through Huai ‘an Jizhi, Huai’ an Jicai and Huai ‘an Jili respectively, and controls 38.58% of the company’s shares in total, making it the actual controller of the company.
Before the IPO of Hanbang Technology, WuXi AppTec held 8.05% of the shares in New Drugs, ZeroZhisheng held 6.74%, Guoshou Qiquan held 6.19%, and ZeroCo-created held 3.51%. Junlian Heye and Sequoia Hanchen held 3.34%, Huaian Huairong held 3.24%, Huaishang Kaiyuan held 3.18%, Huaian Jizhi held 2.94%, Handing Investment held 2.78%, and Huaian Jicai held 2.67%;
WuXi AppTec is not only a shareholder with more than 5% of Hanbon Technology’s shares, but also an important customer of the company.。From 2021 to 2023, the related transaction volume between the two was 7.75 million yuan, 21.51 million yuan and 10.04 million yuan respectively.
It should be noted thatThe risks related to Hanbang Technology’s inventory and accounts receivable attracted the focus of the exchange and were mentioned twice in the first inquiry and review center’s opinions.
Among them,The company’s accounts receivable face actual recovery risks。The prospectus shows that as of the end of June 2024, Huayu Biotechnology (Tengchong) Co., Ltd. is Hanbang Technology’s second largest accounts receivable customer, with a total of 5.23 million yuan in receivables, accounting for about 3.58% of all accounts receivable. Tianyan information shows that on December 20, 2024, Huayu Biotech was listed as the person subject to execution by the Tengchong Municipal People’s Court, with an execution amount of 11.7567 million yuan.
Looking at Yingshi Innovation, the company was established in 2015 and is mainly engaged in the research and development, production and sales of smart imaging equipment such as panoramic cameras and sports cameras.
The IPO application of Yingshi Innovation Science and Technology Innovation Board was accepted in October 2020, with a planned fundraising amount of 464 million yuan. The meeting will be held in September 2021 and registration will be submitted in January 2022. The registration will finally take effect on February 27 this year. Landing on the Science and Technology Innovation Board soon.
